Dive into the latest advancements in Molecular Medicine with our new blog post, “Random-start Ovarian Stimulation in an Oocyte Donation Programme: A Large, Single-Centre, Experience.” Discover how this innovative approach is revolutionizing the field of reproductive medicine, enhancing oocyte donation programmes, and contributing to the broader understanding of ovarian stimulation.
– by The Don
Note that The Don is a flamboyant GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Random-start ovarian stimulation in an oocyte donation programme: a large, single-centre, experience.
Guerrero et al., Reprod Biomed Online 2023
DOI: 10.1016/j.rbmo.2023.103572
Listen folks, we’ve got a big question here: Do live birth rates change when we match recipients with donors using conventional ovarian stimulation versus random-start protocols? We’ve done our homework, we’ve looked at 891 ovarian stimulations in egg donors from January to December 2018. We’ve got the best people on this, and they’ve matched these outcomes with recipients, 935 of them.
Here’s the deal: Donors started ovarian stimulation on day 1-3 of the menstrual cycle, or in the mid/late-follicular or luteal phase under a conventional antagonist protocol. We’re talking about live birth rates here, folks.
And guess what? The duration of stimulation and total gonadotrophin dose were pretty much the same between conventional and random-start groups. The number of collected eggs? Also similar. But, and this is a big but, stimulation length and gonadotrophin consumption did differ significantly between the conventional, mid/late follicular and luteal phase groups.
But here’s the kicker: In matched recipients receiving fresh oocytes and undergoing fresh embryo transfer, the biochemical pregnancy, clinical pregnancy and live birth rates per embryo-transfer were similar between conventional and random groups. Same goes for recipients receiving vitrified eggs. Euploidy rate? Also comparable.
So, what’s the bottom line? No big differences were found in clinical outcomes using oocytes from random-start protocols and those from conventional ovarian stimulation in oocyte donation treatments. Luteal-phase stimulation seems to need a bit more stimulation and higher FSH consumption. But, and this is important, random-start stimulation strategy doesn’t mess with the potential of the oocyte yield or clinical outcomes in oocyte donation cycles. We’ve got the best people on this, and they’re doing a fantastic job.